Global EditionASIA 中文双语Fran?ais
Home / World / Asia-Pacific

兴發体育投注:Sri Lanka sees good results with donated vaccines from China

By ARUNAVA DAS in Kolkata, India and XU WEIWEI in Hong Kong | China Daily Global | Updated: 2021-07-22 09:23 太阳城官网真人荷官
Share - WeChat
A woman receives the Sinopharm vaccine in Colombo, Sri Lanka, on July 15. ISHARA S. KODIKARA/AFP


The COVID-19 vaccine developed by China's Sinopharm Group is highly effective in combating the novel coronavirus, according to a study by a leading university in Sri Lanka, which is speeding up vaccination against the pandemic.

Researchers at Sri Jayewardenepura University found that 95 percent of recipients of the Sinopharm vaccine developed antibodies against SARS-CoV-2, the virus that causes COVID-19.

In addition, the Sinopharm vaccine is also "very effective "against the highly contagious Delta variant, which has spread to 92 countries.

"The antibody responses to the Delta variant, and neutralizing antibodies, were similar to levels seen following natural infection," said Neelika Malavige, head of the SJU immunology and molecular medicine department.

"Although I have not made any head-to-head comparison, it appears that Sinopharm is as good as the world's most effective vaccines," said Malavige, who co-led the study.

China has so far donated 7.1 million doses of Sinopharm vaccines-including a batch of 2 million doses shipped on July 11-to Sri Lanka, which has a population of some 22 million.

Army Commander General Shavendra Silva said a further shipment of 2 million doses was expected in the coming weeks.

The doses have been distributed to vaccinate teachers and school staff across the country, so that schools can reopen as soon as possible. Continuing to keep schools closed because of the virus is not possible, Sri Lankan Minister of Education G.L. Peiris said.

Sri Lanka has relied heavily on the Sinopharm vaccine, according to the country's Ministry of Health. As of Tuesday, 4.63 million Sri Lankans had received the first dose of the Sinopharm vaccine, and 1.29 million others had received the second dose, Xinhua News Agency reported citing ministry data.

Not a single severe side effect has been reported.

"About 95 percent of individuals who received both doses of the vaccine developed antibodies," Malavige said.

She added that the antibody responses to variants like Delta were similar to those observed after a natural COVID-19 infection.

The Sri Lankan study was conducted among 282 people in three age groups. It was funded by the World Health Organization, the UK Medical Research Council, Britain's Foreign and Commonwealth Office, and the Chinese Academy of Medical Sciences' Innovation Fund for Medical Sciences.

Sri Lanka is currently facing a third wave of the COVID-19 with authorities warning of a spread of the Delta variant.

As of Tuesday, Sri Lanka had reported 287,973 COVID-19 cases and 3,870 deaths.

Arunava Das is a freelance journalist for China Daily.

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
太阳城官网真人荷官 88必发电子在线 澳门大三巴真人赌大小 太阳城官网真人荷官 太阳城官网真人荷官
华尔街娱乐在线 申博电子升级模式 菠菜代理在线 永利皇宫开户中心 好运来彩票极速快乐十分
澳门金沙娱乐注册 必發2级会员 下载量最高的棋牌游戏 新2备用网站 金沙赌场城会员开户
19500彩票一分快3 大发棋牌推广二维码 申博在线登入网址 菲律宾申博太阳城游戏登入 银河官网登入